Frontiers in Pharmacology (Jan 2023)

Whole β-glucan particle attenuates AOM/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation

  • Yewen Xie,
  • Yewen Xie,
  • Fang Shao,
  • Fang Shao,
  • Xuehan Duan,
  • Jun Ding,
  • Jun Ding,
  • Yongling Ning,
  • Yongling Ning,
  • Xiao Sun,
  • Lei Xia,
  • Jie Pan,
  • Jie Chen,
  • Shuyan He,
  • Dong Shen,
  • Chunjian Qi,
  • Chunjian Qi

DOI
https://doi.org/10.3389/fphar.2023.1017475
Journal volume & issue
Vol. 14

Abstract

Read online

Yeast β-glucan is a polysaccharide purified from the Saccharomyces cerevisiae cell wall, and its multiple biological activities are essential for immune regulation. However, the effect of β-glucan on the intestinal immune response during colitis-associated colorectal cancer (CAC) is unclear. Here, we explore the possible role of β-glucan in the development of CAC. Wild type (WT) mice with CAC induced by azoxmethane (AOM) and dextran sodium sulfate (DSS) had fewer tumors than untreated mice after oral β-glucan because of increased antitumor dendritic cells (DCs) in the tumor microenvironment, resulting in more CD8+ T cells and the production of related cytokines. β-glucan also increased resistance to DSS-induced chronic colitis by reshaping the inflammatory microenvironment. These data suggest that β-glucan improves experimental intestinal inflammation and delays the development of CAC. Therefore, β-glucan is feasible for treating chronic colitis and CAC in clinical practice.

Keywords